TrialBreast cancer research : BCR2020

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

Ana C Garrido-Castro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.